title: Analysis of multiple factors related to hematologic toxicity following 153Sm-EDTMP therapy.
abstract: OBJECTIVE
  The aim of this study was to investigate the clinical factors related to hematologic toxicity caused by treatment with samarium-153 ethylenediaminetetramethylene phosphonic acid (153Sm-EDTMP).
  
  
  METHODS
  A total of 206 secondary bone neoplasm patients treated with 153Sm-EDTMP were analyzed retrospectively. Logistic regression (SPSS 10.0 for Windows; Chicago, IL) and correlation analysis were used to evaluate the factors concerned.
  
  
  RESULTS
  Age, number of bone metastatic lesions, chemotherapy before treatment with 153Sm-EDTMP, concurrence of radiotherapy, and times of repeated treatments with 153Sm-EDTMP were determined by single factor analysis to be related to hematologic toxicity. Chemotherapy before treatment with 153Sm-EDTMP, concurrence of radiotherapy, drug use to maintain normal white blood cell counts, and times of repeated treatments with 153Sm-EDTMP were determined by multiple factor analysis to be related to hematologic toxicity.
  
  
  CONCLUSIONS
  Chemotherapy before treatment with 153Sm-EDTMP, concurrence of radiotherapy, drug use to maintain normal white blood cell counts, and times of repeated treatments with 153Sm-EDTMP are the main clinical factors related to hematologic toxicity caused by 153Sm-EDTMP therapy. In patients with such factors, more attention might be paid to the change of blood cell counts after 153Sm-EDTMP therapy.
authors.affiliation: Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, People's Republic of China.
authors.forename: Hongbiao
authors.initials: H
authors.lastname: Liu
authors.forename: Hongwei
authors.initials: H
authors.lastname: Zhan
authors.forename: Da
authors.initials: D
authors.lastname: Sun
authors.forename: Wei
authors.initials: W
authors.lastname: Xu
authors.forename: Xiaojuan
authors.initials: X
authors.lastname: Ye
authors.forename: Hong
authors.initials: H
authors.lastname: Zhang
authors.forename: Chunlei
authors.initials: C
authors.lastname: Zhao
authors.forename: Chengkan
authors.initials: C
authors.lastname: Bao
authors.forename: Gangqiang
authors.initials: G
authors.lastname: He
authors.forename: Feng
authors.initials: F
authors.lastname: Yin
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000097:blood* / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D012189:Retrospective Studies